ITM_Logo_Claim_RGB_high-res.png
ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023
June 15, 2023 04:23 ET | ITM Isotope Technologies Munich SE
Garching / Munich, June 15, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will host a multidisciplinary symposium titled,...
ITM_Logo_Claim_RGB_high-res.png
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
June 05, 2023 05:00 ET | ITM Isotope Technologies Munich SE
 One of the largest private investment rounds in European biotech to-dateNet proceeds will enhance ITM’s radiopharmaceutical pipeline, bolster commercial infrastructure, expand leading...
Vantage Market Research.png
Global Radiopharmaceuticals Market Size & Share to Surpass $9.75 Billion by 2030 | Vantage Market Research
May 24, 2023 10:20 ET | Vantage Market Research
WASHINGTON, May 24, 2023 (GLOBE NEWSWIRE) -- The Global Radiopharmaceuticals Market is valued at USD 5.2 Billion in 2022 and is projected to reach a value of USD 9.75 Billion by 2030 at a CAGR...
MicrosoftTeams-image (5).png
Novel Workflow Approaches Create Significant Opportunities in Radiopharmaceuticals Market, as per TMR Study
May 15, 2023 06:30 ET | Transparency Market Research
Wilmington, Delaware, United States, May 15, 2023 (GLOBE NEWSWIRE) -- According to TMR market research, the global radiopharmaceuticals industry growth is expected to be robust owing to rise in...
PSI_Prof. Roger Schibli
ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer
April 27, 2023 05:00 ET | ITM Isotope Technologies Munich SE
Enhancement of ITM’s development and manufacturing activities strengthens ITM’s position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) Garching / Munich, April 27, 2023 – ITM...
84bd90f5-4a1f-42a8-8eb1-5cb062a0b6ac.png
Radiopharmaceuticals Market Predicted to Garner $10.3 Bn by 2032; At a CAGR of 8.85% | Market.us Report
April 19, 2023 16:32 ET | Market.Us
New York, April 19, 2023 (GLOBE NEWSWIRE) -- The Radiopharmaceuticals market recorded a valuation of USD 4.5 billion in 2022 and is expected to reach USD 10.3 billion by the end of 2032, expanding...
DBMR Logo.png
Radiopharmaceuticals Market to Observe Prominent Growth of USD 12.18 Billion by 2030, Size, Share, Trends, Demand, Growth and Competitive Analysis
March 22, 2023 08:14 ET | Data Bridge Market Research
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- A recent study report released by Data Bridge Market research titled “Radiopharmaceuticals Market” (covering USA, Europe, China, Japan, India, South East...
SNS-INSIDER-300X300.jpg
Radiopharmaceuticals Market to Hit USD 10.26 Billion by 2030 due to Increasing Prevalence of Cancer and Cardiovascular Diseases Worldwide
March 17, 2023 10:07 ET | SNS Insider pvt ltd
Pune, March 17, 2023 (GLOBE NEWSWIRE) -- The size for Radiopharmaceuticals Market was valued at USD 5.07 billion in 2022 and is projected to reach USD 10.26 billion by 2030, with a Compound Annual...
LOGO.jpg
QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
February 28, 2023 08:00 ET | QSAM Biosciences Inc.
Austin, TX, Feb. 28, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
LOGO.jpg
QSAM Biosciences Provides 2022 Update and 2023 Milestones to Shareholders
January 10, 2023 07:00 ET | QSAM Biosciences Inc.
AUSTIN, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...